Di Bartolomeo, M., Niger, M., Morano, F., Corallo, S., Antista, M., Tamberi, S., . . . Pietrantonio, F. (2019). Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial. BMC Cancer.
Styl ChicagoDi Bartolomeo, Maria, et al. "Assessment of Ramucirumab Plus Paclitaxel As Switch Maintenance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: The ARMANI Phase III Trial." BMC Cancer 2019.
Citace podle MLADi Bartolomeo, Maria, et al. "Assessment of Ramucirumab Plus Paclitaxel As Switch Maintenance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: The ARMANI Phase III Trial." BMC Cancer 2019.